Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDX
· Real-Time Price · USD
27.34
0.87 (3.29%)
At close: Oct 15, 2025, 3:59 PM
26.91
-1.57%
After-hours: Oct 15, 2025, 04:21 PM EDT
Celldex Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 7.02M | 6.88M | 2.36M | 4.65M |
Cost of Revenue | 3.18M | 3.01M | 1.4M | 3.07M |
Gross Profit | 7.02M | -111.13M | -79.9M | 1.58M |
Operating Income | -195.08M | -154.54M | -115.23M | -71.24M |
Interest Income | 37.22M | 13.11M | 2.91M | 505K |
Pretax Income | -157.86M | -141.43M | -112.33M | -70.74M |
Net Income | -157.86M | -141.43M | -112.33M | -70.51M |
Selling & General & Admin | 38.55M | 30.91M | 27.2M | 20.49M |
Research & Development | 163.55M | 118.01M | 82.26M | 50.24M |
Other Expenses | n/a | -105.51M | -74.12M | -48.15M |
Operating Expenses | 202.1M | 43.41M | 35.33M | 22.58M |
Interest Expense | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 202.1M | 161.43M | 117.59M | 75.89M |
Income Tax Expense | n/a | n/a | n/a | -227K |
Shares Outstanding (Basic) | 64.39M | 48.45M | 46.89M | 42.87M |
Shares Outstanding (Diluted) | 64.39M | 48.45M | 46.89M | 42.87M |
EPS (Basic) | -2.45 | -2.92 | -2.4 | -1.64 |
EPS (Diluted) | -2.45 | -2.92 | -2.4 | -1.64 |
EBITDA | -191.9M | -139.03M | -104.2M | -66.08M |
EBIT | -195.08M | -142.04M | -107.1M | -69.15M |
Depreciation & Amortization | 3.18M | 3.01M | 2.9M | 3.07M |
Source: Financial Modeling Prep. Financial Sources.